Quick Answer
NovoCure Ltd reported Cash And Cash Equivalents At Carrying Value of $93.55 million for the year ending 2025.
- NovoCure Ltd showed a decrease of -42.9% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from NovoCure Ltd's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $79.98 million | Q1 2015: $74.22 million | Q2 2015: $106.51 million | Q3 2015: $110.32 million | Q1 2016: $115.93 million | Q2 2016: $80.87 million | Q3 2016: $115.82 million | Q1 2017: $84.59 million | Q2 2017: $80.19 million | Q3 2017: $82.10 million | Q1 2018: $111.60 million | Q2 2018: $114.46 million | Q3 2018: $122.96 million | Q1 2019: $152.07 million | Q2 2019: $180.07 million | Q3 2019: $208.03 million | Q1 2020: $181.92 million | Q2 2020: $196.78 million | Q3 2020: $234.46 million | Q1 2021: $314.55 million | Q2 2021: $349.12 million | Q3 2021: $689.84 million | Q1 2022: $190.74 million | Q2 2022: $367.01 million | Q3 2022: $243.81 million | Q1 2023: $185.96 million | Q2 2023: $156.98 million | Q3 2023: $154.86 million | Q1 2024: $453.76 million | Q2 2024: $164.80 million | Q3 2024: $185.42 million | Q1 2025: $127.28 million | Q2 2025: $149.62 million | Q3 2025: $342.12 million.
- Over the full 14 years of available data (2012 to 2025), NovoCure Ltd's Cash And Cash Equivalents At Carrying Value has grown by 168.1%.
- Historical annual values: Fiscal year 2025: $93.55 million | Fiscal year 2024: $163.77 million | Fiscal year 2023: $240.82 million | Fiscal year 2022: $115.33 million | Fiscal year 2021: $208.80 million | Fiscal year 2020: $234.67 million | Fiscal year 2019: $177.32 million | Fiscal year 2018: $140.62 million | Fiscal year 2017: $78.59 million | Fiscal year 2016: $99.78 million | Fiscal year 2015: $119.42 million | Fiscal year 2014: $57.61 million | Fiscal year 2013: $175.89 million | Fiscal year 2012: $34.89 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: